公司資料
Keros Therapeutics 股價、新聞與催化劑
- 股票代碼:
- KROS
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
10.78 USD (-2.27%)
收盤價
最後更新: 2026年8月24日
209M USD
市值
股價為何變動
As of Aug 24, 2026, KROS closed down 2.27% at $10.78. No new same-company headline was identified in the current news window.
公司概覽
TGF-β Biology Platform
Keros Therapeutics develops protein therapeutics for diseases linked to dysfunctional signaling within the transforming growth factor-beta family, which regulates muscle, bone, adipose tissue, cardiac tissue, and blood-cell development.
Rinvatercept
Rinvatercept is the company’s lead internally controlled candidate and is being developed for Duchenne muscular dystrophy and amyotrophic lateral sclerosis.
Elritercept Partnership
Elritercept targets cytopenias, including anemia and thrombocytopenia, in myelodysplastic syndromes and myelofibrosis. Takeda has assumed development responsibility under a licensing partnership.
未來催化劑
- Takeda plans to advance elritercept into a Phase 3 trial for anemia in myelofibrosis.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。